Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
Gao J, Wang MY, Ren Y, Lwin T, Li T, Yan JC, Sotomayor EM, Duckett DR, Shah BD, Shain KH, Zhao X, Tao J. Gao J, et al. Among authors: sotomayor em. Haematologica. 2022 May 1;107(5):1119-1130. doi: 10.3324/haematol.2021.278743. Haematologica. 2022. PMID: 34162179 Free PMC article.
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham LV, Sudalagunta PR, Wan L, Wang X, Dalton WS, Moscinski LC, Shain KH, Vose J, Cleveland JL, Sotomayor EM, Fu K, Tao J. Ren Y, et al. J Clin Invest. 2018 Dec 3;128(12):5517-5530. doi: 10.1172/JCI122533. Epub 2018 Nov 5. J Clin Invest. 2018. PMID: 30260324 Free PMC article.
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Zhang X, et al. Among authors: sotomayor e. Cancer Cell. 2012 Oct 16;22(4):506-523. doi: 10.1016/j.ccr.2012.09.003. Cancer Cell. 2012. Retraction in: Cancer Cell. 2023 Jun 12;41(6):1198. doi: 10.1016/j.ccell.2023.05.003 PMID: 23079660 Free PMC article. Retracted.
PRDM1 is required for mantle cell lymphoma response to bortezomib.
Desai S, Maurin M, Smith MA, Bolick SC, Dessureault S, Tao J, Sotomayor E, Wright KL. Desai S, et al. Among authors: sotomayor e. Mol Cancer Res. 2010 Jun;8(6):907-18. doi: 10.1158/1541-7786.MCR-10-0131. Epub 2010 Jun 8. Mol Cancer Res. 2010. PMID: 20530581 Free PMC article.
176 results